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Abstract Genome-wide association studies have revealed
that single-nucleotide polymorphisms in the first intron of the
gene encoding fat mass and obesity-associated protein (FTO)
are robustly associated with BMI and obesity. Subsequently,
this association with body weight, which is replicable across
multiple populations and different age groups, has been
unequivocally linked to increased food intake. Although
evidence from a number of animal models with perturbed
FTO expression indicates a role for FTO in energy homeosta-
sis, to date, no conclusive link has been made between the risk
alleles and FTO expression or its physiological role. FTO is a
nucleic acid demethylase, and a deficiency in FTO leads to a
complex phenotype highlighted by postnatal growth retarda-
tion, pointing to some fundamental developmental role. Recent
emerging data now points to a role for FTO in the sensing of
nutrients and the regulation of translation and growth. In this
review, we explore the in vivo and in vitro evidence detailing
the complex biology of FTO and discuss how these might link
to the regulation of body weight.
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Until quite recently, obesity was largely confined to
industrialised countries of the developed world, but its preva-
lence is now increasing rapidly in the urban centres of emerg-
ing economies. In fact, it would not be an exaggeration to
classify obesity as a major public health issue now reaching
worldwide epidemic proportions [1]. The underlying cause of
obesity is clearly the consumption of more energy than is
expended, and the rapid changes in lifestyle and food avail-
ability over the past 30 years have undeniably driven this rise
in obesity. Themore difficult and far more interesting question,
however, is why some people eat more than others. Individuals
respond differently to ‘obesigenic’ environmental changes and
an increasing weight of evidence points to a potent genetic
element underlying this variation in response. Indeed, studying
the correlations of BMI in monozygotic, dizygotic, biological
and adopted siblings reveals the heritability of fat mass to be
between 30% and 70% [2–5]. Consequently, genetic ap-
proaches offer a powerful tool for characterising the molecular
and physiological mechanisms of food intake and body weight
control, and allow us to understand how these may become
ineffective in the obese state.
Over the past 20 years, insights from human and mouse
genetics have illuminated multiple pathways within the brain
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that play a key role in the control of food intake (reviewed by
[6]). We now know, for example, that the hypothalamic leptin–
melanocortin signalling pathway is crucial for the appropriate
control of food intake, with genetic disruption of most com-
ponents of the pathway resulting in severe obesity in both
mouse and man. However, these and other monogenic syn-
dromes of severe obesity remain very rare. The major burden
of disease is carried by those with ‘common obesity’, which
until recently, largely as a result of a lack of sufficient statistical
power, resisted yielding meaningful biological insights.
In 2007, the advent of technology enabling the epony-
mous genome-wide association studies (GWAS) led to the
identification of the gene encoding fat mass and obesity-
associated protein (FTO) [7–9], the first of the so-called
‘post-genomics’ obesity genes. Since then more than a hun-
dred other candidate genes that are associated with obesity-
related traits have been identified [10]. FTO remains statis-
tically the most robust gene and with the largest effect size.
However, to date, FTO’s physiological role and its link to
body weight regulation remain unclear. Emerging data from
our laboratory now points to a role for FTO in the sensing of
nutrients and the regulation of translation and growth [11]. In
this review, we explore the in vivo and in vitro evidence
detailing the complex biology of FTO and discuss how this
might link to the regulation of body weight.
Identification of FTO
In 2007, Frayling and colleagues performed a GWAS to
identify type 2 diabetes susceptibility genes and reported that
multiple single-nucleotide polymorphisms (SNPs) in the first
intron of FTO were associated with disease [8]. However, the
association between these FTO SNPs and type 2 diabetes
disappeared after adjustment for BMI. Given that body weight
is a risk factor for type 2 diabetes, it was suggested that these
SNPs are actually associated with BMI [8]. Two subsequent
reports, a French study [7] and a Sardinian study [9], closely
followed, confirming a robust association between FTO SNPs
and body weight. Many other studies have now examined and
confirmed the influence of FTO variants on BMI across
multiple populations and age groups (reviewed by [12]).
Recent studies have reported that the association of the
FTO risk allele with the odds of obesity is attenuated by 27%
in adults who are more physically active [13], highlighting
the importance of exercise in influencing the ‘genetic bur-
den’ of the FTO risk alleles. This is consistent with observa-
tions that between-person variability in obesity can also
partly be explained by the genotype at the FTO locus [14].
In other words, although carriers of the FTO risk allele have
an increased mean BMI, there is also increased variability of
effect size around the mean, which is likely to be influenced
by the impact of exercise and other environmental factors.
When the influence of FTO on body weight is studied
in more detail, particularly with respect to the component
aspects of the energy balance equation, it is unequivocal
that the major effect of FTO ‘risk alleles’ is an increase
in energy intake [15–20], with a reduction in satiety
[21, 22] and possibly with an increased daily fat intake
[19, 23]. In contrast, the evidence for involvement of
mechanisms involving energy expenditure in the effect
of FTO on human adiposity, either as altered basal
energy utilisation [16, 18, 24–26] or physical activity
[24, 27–29] is, to date, less compelling.
FTO or not FTO?
However, although GWAS has been incredibly powerful,
providing valuable insights into the genetic architecture of
complex diseases and traits, it is important to consider the
limitations of what is, in effect, a gene-agnostic approach.
SNPs reaching the appropriate statistical threshold for asso-
ciation with disease can appear anywhere in the genome, and
very rarely occur within any coding sequence. The current
assumption that the closest coding region, which is some-
times hundreds of kilobases away, is the likely candidate is
certainly a reasonable first guess, but until empirically prov-
en, is not necessarily true [30, 31].
In this instance, the FTO risk alleles are actually located in
the first intron of the FTO gene. However, they are also very
close to the transcriptional start site of RPGRIP1L (the hu-
man orthologue of mouse Ftm), which is adjacent to and
coded for on the opposite DNA strand to FTO [32]. There
were two main reasons why the focus of study began with
FTO and not RPGRIP1L: (1) unlike FTO, expression of
RPGRIP1L, which is known to localise in the primary cilia
and centrosomes of ciliated cells, is not nutritionally regu-
lated [33]; Second, defects in human RPGRIP1L exist and
cause Joubert syndrome type 7 (JBTS), which presents clin-
ically with a peculiar cerebellar and brainstem malformation
and renal failure [34]. The patients do not present with any
obvious bodyweight-related phenotypes, with the caveat that
any potential ‘lean’ phenotype is difficult to ascertain in a
healthy individual, let alone someone who is severely ill.
Deletion of the mouse orthologue Ftm recapitulates the ce-
rebral, renal and hepatic defects seen in JBTS patients [34].
There is, however, evidence for possible co-regulatory
mechanisms between FTO and RPGRIP1L. Stratigopoulos
et al report an overlapping regulatory region within intron 1
of FTO that contains at least two putative transcription factor
binding sites (CUTL1), one of which overlaps with another
obesity-associated SNP (rs8050136) [32]. It certainly is a
possibility that the association between FTO SNPs and body
weight regulation is mediated through changing the expres-
sion of both FTO and RPGRIP1L.
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From an ‘unknown unknown’ to a nucleic acid
demethylase
Because of its ‘hypothesis-free’ nature, the power of GWAS
lies in uncovering potentially new biology that would not
have been possible using a candidate gene approach. The
problem with new biology, of course, is that by definition,
little or nothing at all might be known about the gene. This
was certainly true for FTO, which, when first identified, to
memorably quote Frayling and colleagues from 2007, was ‘a
gene of unknown function in an unknown pathway’ [8].
Using bioinformatic tools we and our colleagues reported
that FTO belongs to the superfamily of Fe(II) 2-oxoglutarate
(2-OG)-dependent dioxygenases, with highest sequence
similarity to the Escherichia coli DNA repair enzyme AlkB
and its mammalian AlkB homologues 2 and 3 (ABH2 and 3)
[33]. We and others showed that, in an in vitro assay, FTO is
able to catalyse the Fe(II)- and 2-OG-dependent demethyla-
tion of 3-methylthymine and 3-methyluracil (3meU) in
single-stranded DNA and RNA to thymine and uracil, re-
spectively (Fig. 1) [33, 35]. Subsequently, Jia et al reported
that N6-methyladenosine (6meA) in both DNA and RNA is
yet another substrate of FTO, but one with 50-fold greater
affinity for the enzyme compared with 3meU [36]. While
3meU is found largely in ribosomal RNA (rRNA) [37],
6meA is the most common modified nucleoside found in
mRNA [38]. However, because rRNA accounts for the vast
majority of total RNA, in absolute terms, there is actually a
hundredfold more 3meU than 6meA in any given cell. It is
still not entirely clear whether one or both of these modified
bases is the endogenous substrate/s for FTO.
The crystal structure of FTO is available, providing a basis
for the study of structure–function relationships of FTO [39].
The FTO protein comprises two domains, an N-terminal
domain containing the catalytic core, and a C-terminal domain
with an as yet unknown function/role. The catalytic domain of
FTO contains five obligate amino acid residues found in all
members of this enzyme superfamily, which are required for
2-OG and Fe(II) binding. FTO also possesses an additional
region, referred to as Loop 1, which is highly conserved
among FTO proteins from different species but is absent from
other members of the ALKBH family of proteins. Through
steric hindrance of the substrate binding pocket, the Loop 1
region is thought to give FTO specificity for single-stranded
nucleic acids during substrate binding [39].
FTO deficiency
There are several examples in metabolic disease where com-
mon variants close to a particular gene are associated with
alterations in risk of common phenotypes such as fat mass or
risk of obesity, whereas rare loss- or gain-of-function muta-
tions in the same gene are associated with a more severe
version of the same metabolic phenotype (e.g. MCR4
[40–43], POMC [44, 45], BDNF [46–48] and PCSK1 [49,
50]). As it turns out, however, the phenotype seen in FTO
deficiency proved far more complicated.
FTO was actually first identified as part of a 1.6 Mb
deletion in the Fused toes mouse mutant [51]. This deletion
included not only Fto, but also Ftm, Ftl and the Iroquois B
cluster, consisting of Irx3, Irx5, and Irx6. Fused toes mutants
display severe developmental defects, such as left–right
asymmetry [52], polydactyly and defects in hypothalamus
development [52, 53]. While the homozygotes are embryon-
ically lethal, heterozygous mice have fused digits and hyper-
plasia of the thymus without any metabolic alterations. In
contrast, mice with a specific targeted deletion of Fto did not
display these severe developmental abnormalities, but
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retardation, decreased fat and lean body mass and elevated
food intake when corrected for lean body mass [54]. There
was also a significant level of postnatal lethality, with only
50% of homozygous pups reaching weaning age [54, 55].
Humans with a homozygous loss-of-function R316Q
mutation in FTO displayed an equally complex phenotype
[56]. Like the Fto-null mice, these patients exhibited severe
postnatal growth retardation. In addition, however, they
also displayed microcephaly, psychomotor delay, facial
dysmorphism, certain brain malformations and cardiac
abnormalities. Tragically, none of the patients survived
beyond the age of 3 years. The arginine at position 316 is
one of the critical amino acid residues that interacts with
2-OG, which when mutated renders FTO catalytically
inactive and unable to demethylate [56]. The phenotypes
seen in the patients with the R316Q mutation and in the
Fto-deficient mice provide direct evidence that FTO, in
particular its demethylase activity, plays some fundamental
role in the control of growth and development.
Fto overexpression
Church and colleagues have generated a ‘knock-in’ mouse
model that carries one or two additional copies of Fto [57].
Mice overexpressing Fto showed a dramatic increase in food
intake resulting in a marked increase in body weight and fat
mass when they were fed either chow or a high-fat diet.
There was no significant change in either energy expenditure
or physical activity. Although the increase in weight with the
overexpression of Fto seems consistent with FTO deficiency
resulting in a ‘lean’ phenotype, the increase in food intake
seen in these mice is not. Curiously, at the age of 8 weeks,
mice overexpressing Fto had reduced leptin levels after an
overnight fast compared with wild-type controls [57]. It
should be noted that these are obese mice with increased
fat mass, that in the wild-type state should normally respond
with increased leptin levels. The authors of the study do
comment that the hyperphagic phenotype is possibly due to
an FTO-dependent reduction of leptin [57], although no
mechanistic details are provided.
Tissue-specific perturbation of FTO expression
FTO is expressed ubiquitously in human and animal tissues,
with the highest expression seen in the brain.Within the brain,
FTO expression is relatively high in a number of hypothalam-
ic nuclei, namely, the arcuate (ARC), paraventricular,
dorsomedial, and ventromedial nuclei, where control of ener-
gy homeostasis is centred [33].Within the ARC, expression of
Fto is bi-directionally regulated as a function of nutritional
status, decreasing following a 48 h fast and increasing after
10 weeks of exposure to a high-fat diet [33, 58]. If FTO had a
direct action on the control of energy intake, one would
predict that reducing its expression would recapitulate the
fasting state, thereby resulting in an increase in food intake.
This does indeed seem to be the case. Tung et al knocked
down and overexpressed FTO specifically in the ARC in rats,
using adeno-associated virus vectors coupled with stereotactic
injections. When FTO is overexpressed, food intake is re-
duced. Conversely, reducing FTO expression increases food
intake [58].
The region-specific manipulation of FTO provides further
support for the notion that, by acting specifically in the ARC
of the hypothalamus, FTO itself can influence energy ho-
meostasis by having a direct effect on food intake. These
findings are consistent with the robust association between
the FTO risk alleles and increase in food intake. Mice with
central nervous system (CNS)-specific deletion of Fto have
now been generated [59]. Surprisingly, these brain-specific
Fto-deficient mice recapitulate the phenotype of the whole
body knockouts, although this has yet to be exhaustively
examined [59]. This suggests that an important proportion
of the function of FTO, particularly its link to the regulation
of energy homeostasis, is mediated in the brain.
On a related note, in addition to BMI, the risk alleles in
FTO have also been associated with a number of other, what
could be considered neurological phenotypes. These include
decreased brain volume both in adolescents [60] and the
elderly [61], increased incidence of attention deficit-
hyperactivity disorder [62], depression [63] and alcohol de-
pendence [64], as well as an increased risk of Alzheimer’s
disease [65]. It is difficult to really know at this point whether
these associations are dependent or independent of FTO’s
effect on BMI.
FTO is not a sensor for 2-OG
Given the evidence above that FTO can influence food
intake, we began to explore whether FTO could be acting
as a nutrient (in its broadest sense) sensor. Because 2-OG, a
key intermediate in the citric acid cycle, is a co-substrate of
FTO, we considered whether FTO functions as a sensor for
intracellular concentrations of this metabolite and, thus, cel-
lular metabolism. To this end, our laboratory developed a
high-throughput fluorescence-based FTO activity assay [66].
This assay is based on the principle that RNase A selectively
cleaves the phosphodiester bond 3- of unpaired pyrimidine
residues and that a methyl group on N3 of the uracil base
(3-meU) would inhibit the ability of RNase A to cleave. We
engineered a stem–loop structure with a DNA-based stem
and a loop derived from RNA, which contains a 3-meU as
the sole pyrimidine in the middle of the loop. Utilising this
stem–loop structure as a substrate in the FTO activity assay,
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we demonstrated that FTO can demethylate 3-meU in this
microlitre-scale assay. As 2-OG acts as a co-substrate, we
could then apply this assay to examine the enzyme kinetics
of FTO with regards to its usage of 2-OG, arriving at a 2-OG
Km value for FTO of 2.88 μmol/l. Since typical intracellular
concentrations of 2-OG are measured to be more than tenfold
higher, at around 50–100 μmol/l, it is clear that, although
required for FTO activity, it is unlikely that the physiological
role of FTO is to sense 2-OG [66].
FTO levels are regulated by availability of essential
amino acids
In another study, we used an in vitro approach to determine
which nutrients could regulate FTO concentrations at a cel-
lular level [67]. We found that FTO mRNA and protein
levels are dramatically downregulated by total amino acid
deprivation in mouse hypothalamic N46 cells, mouse em-
bryonic fibroblasts (MEFs) and in human embryonic kidney
293 (HEK 293) cells. The fall in expression of Fto mRNA is
faster than its rate of natural degradation, pointing to some
regulation at the transcriptional level, which is reversible upon
amino acid replacement. Strikingly, this downregulation was
seen only with deprivation of essential amino acids. These
data suggest that there might be some interplay between FTO
levels and essential amino acid availability [67].
A role for FTO in cell growth and mRNA translation
Could the regulation of FTO expression by amino acids then
be linked to the growth retardation phenotype seen in FTO
deficiency? In a recent study, we showed that MEFs derived
from Fto−/− mice exhibit slower rates of growth and have
reduced mRNA translation compared with wild-type MEFs
[11]. Aminoacyl-tRNA synthetases (AARSs), which tether
free AAs to their cognate tRNAs in a process known as
‘tRNA charging’, are one of the key modulators of mRNA
translation. During tRNA charging, at least nine different
AARSs work together as a part of large multimer complex
known as the multi-synthetase complex (MSC) [68]. The
maintenance of the MSC is essential for mRNA translation,
and disruption of the MSC leads to a reduction in protein
levels of member AARSs and a concomitant drop in AARS
activity, leading to reduced mRNA translation rates [69].
Consistent with the reduced rates of translation, Fto−/−
MEFs have reduced protein levels of MSC components.
The defects in mRNA translation and reduced levels of
MSC components in Fto−/− MEFs are rescued by re-
expressing exogenous FTO in these cells [11]. These results
indicate a role for FTO in the regulation of mRNA transla-
tion through maintenance of cellular MSC protein levels.
FTO links amino acid availability to mTORC1 signalling
As a key regulator of both cell growth and mRNA translation
that is sensitive to amino acid levels, we measured the status
of mammalian target of rapamycin complex 1 (mTORC1)
signalling in Fto−/− MEFs. Cells lacking FTO display de-
creased activation of the mTORC1 pathway, decreased rates
of mRNA translation and increased autophagy [11]. It makes
mechanistic sense that these changes are likely to contribute
to the stunted growth phenotype seen in Fto−/−mice [54] and
in humans homozygous for loss-of-function FTO mutations
[56]. The dramatic regulation of FTO by amino acids [67]
appears to be necessary for the physiological response to
fluctuating amino acid levels, as expression of exogenous
FTO in cells renders them insensitive to amino acid depri-
vation by preventing the expected reduction in mTORC1
signalling [11]. Critically, using the catalytically inactive
R316Qmutant of FTO [56], we showed that the link between
amino acid availability and mTORC1 signalling is depen-
dent upon the demethylase activity of FTO [11].
The role of AARSs in mTORC1 activation has recently
taken centre stage, with recent reports implicating leucyl-
tRNA synthetase (LRS) as a key amino acid sensor upstream
of Ras-related GTPase (RAG) and mTORC1 [70, 71]. When
we measured LRS levels in Fto−/− MEFs, we found that, as
with the other AARSs, expression of LRS is reduced in re-
sponse to a lack of FTO [11]. Thus, taken in context with these
recently published data, we suggest a model whereby FTO is
upstream of one of the AARSs (LRS) in the link between
amino acid levels and mTORC1 signalling, leading to appro-
priate regulation of mRNA translation rates and cell growth
(Fig. 2a). In the absence of FTO, mTORC1 signalling is
dysregulated, putting cells into amino acid deprivation-like
conditions even in the presence of amino acids (Fig. 2b).
Adult deletion of FTO leads to loss of lean mass
Additional evidence supporting a role for FTO in the regu-
lation of translation and growth has recently been provided
[55]. When FTO is deleted in adult mice, using a tamoxifen-
driven Cre recombinase conditional deletion approach, the
mice begin to lose weight almost immediately. Intriguingly,
there is no reduction of fat mass, with all of the change in
weight down to a dramatic loss in lean mass [55]. The
sudden loss of FTO expression deprives a cell of the ability
to respond appropriately to amino acids, in effect depriving a
cell of amino acids, which, as discussed above, would reduce
mTORC1 signalling and increase autophagy (Fig. 2b). Au-
tophagy is the basic catabolic mechanism that involves the
cellular degradation of unnecessary or dysfunctional cellular
components through the lysosomal machinery. This break-
down of cellular components, including proteins, can also
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ensure cell survival during starvation by maintaining
cellular energy levels. As skeletal muscle is the largest
depot of protein in the body, it appears to be the most
sensitive to the sudden removal of FTO and subsequent
increase in autophagy, leading to a dramatic loss of
muscle mass. In contrast, when FTO is postnatally de-
leted specifically from the mediobasal hypothalamus,
there is a more subtle weight loss, resulting from a
change in food intake [55].
The 6meA methylome
A critical question not answered by these latest findings is:
how does the catalytic function of FTO as a demethylase lead
to its regulation of mTORC1 signalling? One possibility
could involve FTO’s ability to demethylate 6meA. Two
recently published studies have used antibodies against
6meA to immunoprecipitate human and mouse transcripts
that carry the 6meA modification, and subjected the ‘pulled-
down’material to RNA sequencing, allowing both groups to
map the presence of 6meA in a transcriptome-wide manner
[72, 73]. As it turns out, 6meAs are common and are highly
conserved between mice and man. Crucially, 6meAs are
dynamically regulated, both in terms of development and
tissue specificity. These studies have far-reaching implica-
tions, as the presence of 6meA at appropriate mRNA sites
appears to play a fundamental regulatory role in mRNA
translation, in addition to exerting varying effects on mRNA
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Fig. 2 Proposed model for FTO as an amino acid sensor. We suggest a
model whereby FTO is upstream of AARS (LRS) in the link between
amino acid levels and mTORC1 signalling, leading to appropriate
levels of translation and growth (a). In the absence of FTO, mTORC1
signalling is dysregulated, putting cells into amino acid deprivation-like
conditions even in the presence of amino acids (b). Solid outlines
around FTO, AARS, MSC and LRS indicate maintenance of levels,
while dashed outlines indicate reduced levels of expression. AAs,
amino acids; AARS, amino-acyl tRNA synthetase; LRS, leucyl-tRNA
synthetase; MSC, multi-synthetase complex; RAG, Ras-related
GTPase; mTORC1, mammalian target of rapamycin complex 1
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To date, only one enzyme—methyltransferase like 3
(METTL3)—has been identified as catalysing the conver-
sion of adenosine to 6meA [74]. Critically, and relevant to
our discussion, two enzymes are currently known to catalyse
the removal of this methyl group: ALKBH5 [75] and FTO
[36, 73]. In fact, Meyer and colleagues have shown that
transient overexpression of FTO in HEK 293 cells decreases
the total amount of 6meAs found in the transcriptome [73].
An area of intense study is now aimed at understanding the
repertoire of mRNAs that are demethylated by FTO and
whether these lead to changes in rates of mRNA translation.
What is the role of FTO in obesity?
So, for the 64 million dollar question: how do these findings
relate to the association between FTO SNPs and obesity?
The short answer is, we still do not know. The biggest hurdle
remains the fact that we do not know if or how the FTO risk
alleles influence FTO. Considering the intronic location of
all the FTO obesity-related SNPs (spanning across ∼40 kb),
they are unlikely to cause functional mutations. Instead, the
SNPs are more likely to be playing a transcriptional regula-
tory role, either to up- or downregulate FTO expression.
What is clear, as has been demonstrated in multiple stud-
ies, is that the association of FTO with BMI is largely driven
by effects on appetite and food intake [15–20]. However,
unlike the comparatively unambiguous examples from the
leptin–melanocortin pathway, the study of humans and mice
with disruptions in FTO has not been a panacea for our
understanding of FTO function. That said, enough evidence
has emerged from the complex phenotype seen in in vivo
models where its expression is perturbed to support a role for
FTO in the regulation of energy homeostasis. For example,
Fto+/− mice are resistant to high-fat-diet-induced obesity
[54]; ‘knocking-in’ one or two extra copies of Fto dose-
dependently increases body weight [57]; and manipulating
the expression of FTO within the hypothalamus, where it is
nutritionally regulated, can influence food intake [58].
How does this in vivo evidence relate to the cellular role
of FTO in the sensing of amino acids? FTO is ubiquitously
expressed, and all evidence to date indicates that its role in
linking amino acid levels to mTORC1 signalling would be
conserved in all cell types. We argue that any apparent
‘tissue-specific’ action of FTO would thereby reflect the
key functions of the tissue being studied, as opposed to any
different role for FTO itself. The sudden loss of muscle mass
in response to the adult-specific deletion of FTO in the
mouse (see above) is one case in point. Likewise, we
hypothesise that the role of FTO in the regulation of food
intake is also linked to its function in the sensing of amino
acids. FTO is most highly expressed in the hypothalamus
[33], where the sensing of amino acid levels has been
demonstrated to affect orexigenic and anorexigenic path-
ways controlling food intake [76]. Keeping in mind the
modest effect size of around 1.5 kg per FTO risk allele in
humans (with homozygote carriers being on average 3 kg
heavier), we suggest that the risk alleles result in subtle
variations in the expression of FTO in key appetite control
centres within the brain, which are likely to influence the
way in which we sense and therefore respond to amino acid
levels. Human carriers for the FTO risk SNPs actually dis-
play quite a nuanced feeding phenotype compared with non-
carriers. In test meals, they not only consume more calories
in absolute terms, but also show an alteration in nutrient
preference [77], supporting our contention that perhaps one’s
FTO status can influence the direct sensing of dietary mac-
ronutrient content by the brain. The proposed cellular role for
FTO in amino acid sensing provides some clues towards
understanding the basis for this physiological phenomenon.
Future perspectives: is FTO a drug target?
Given the fact that 50% of the world’s population are carriers
of FTO ‘risk’ alleles, and therefore have their body weight
subtly influenced by FTO, a reasonable question to ask is:
can FTO ever be considered a viable pharmaceutical target?
Given its ubiquitous expression, the severity of the pheno-
type seen in human and murine FTO deficiency, and the fact
that adult deletion of FTO results in a dramatic loss of muscle
mass, we believe that this is unlikely. However, understand-
ing the biology of FTO and its downstream actions could
potentially reveal novel therapeutic targets in our battle
against the increasing epidemic of obesity. We believe that
our efforts to date in turning the statistical association of FTO
into a deeper understanding of its biology could form a
template of how to approach the many other emerging
GWAS obesity genes of unknown function.
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